References
- Faergemann J, Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol 2003;149:1–4
- Shivakumar HN, Juluri A, Desai BG, Murthy SN. Ungual and transungual drug delivery. Drug Dev Ind Pharm 2012;38:901–11
- Gupta AK, Uro M, Cooper EA. Onychomycosis therapy: past, present, future. J Drugs Dermatol 2010;9:1109–13
- Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992;43:259–84
- Elkeeb R, Alikhan A, Elkeeb L, et al. Transungual drug delivery: current status. Int J Pharm 2012;384:1–8
- Hall M, Monka C, Krupp P, O’Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol 1997;133:1213–19
- Thomas J, Jacobson GA, Narkowicz CK, et al. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther 2010;35:497–519
- Effendy I, Lecha M, Feuilhade De Chauvin M, et al. Epidemiology and clinical classification of onychomycosis. J Eur Acad Dermatol Venereol 2005;19:8–12
- Kokjohn K, Bradley M, Griffiths B, Ghannoum M. Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria. Int J Dermatol 2003;42:11–17
- Selner M, inventor. Penetrating carrier, anti-fungal composition using the same and method for treatment of dermatophytes. United States patent 7601371; 13 Oct 2009
- Selner M, inventor. Penetrating carrier, anti-fungal composition using the same and method for treatment of dermatophytes. United States patent 7597913; 6 Oct 2009
- Hui X, Shainhouse Z, Tanojo H, et al. Enhanced human nail drug delivery: nail inner drug content assayed by new unique method. J Pharm Sci 2002;91:189–95
- Hui X, Wester RC, Maibach HI. Nail penetration. In: Baran B, Maibach HI, eds. Textbook of cosmetic dermatology 4th ed. New York: Informa Healthcare; 2010:63–72
- Brown MB, Khengar RH, Turner RB, et al. Overcoming the nail barrier: a systematic investigation of ungual chemical penetration enhancement. Int J Pharm 2009;370:61–7
- Malhotra GG, Zatz JL. Investigation of nail permeation enhancement by chemical modification using water as a probe. J Pharm Sci 2002;91:312–23
- Walters KA, Abdalghafor HM, Lane ME. The human nail – barrier characterisation and permeation enhancement. Int J Pharm 2012;435:10–21
- Traynor MJ, Turner RB, Evans CR, et al. Effect of a novel penetration enhancer on the ungual permeation of two antifungal agents. J Pharm Pharmacol 2010;62:730–7
- Monti D, Saccomani L, Chetoni P, et al. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity. Br J Dermatol 2010;162:311–17
- Hui X, Chan TC, Barbadillo S, et al. Enhanced econazole penetration into human nail by 2-n-nonyl-1,3-dioxolane. J Pharm Sci 2003;92:142–8
- Murdan S. Drug delivery to the nail following topical application. Int J Pharm 2002;236:1–26
- Franz TJ. Absorption of amorolfine through human nail. Dermatology 1992;184:18–20
- Stüttgen G, Bauer E. Bioavailability, skin- and nailpenetration of topically applied antimycotics. Mykosen 1982;25:74–80
- Mertin D, Lippold BC. In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: penetration of chloramphenicol from lipophilic vehicles and a nail lacquer. J Pharm Pharmacol 1997;49:241–5
- Hui X, Chan TC, Barbadillo S, et al. Enhanced econazole penetration into human nail by 2-n-nonyl-1,3-dioxolane. J Pharm Sci 2003;92:142–8
- Walters KA, Flynn GL, Marvel JR. Physicochemical characterization of the human nail: permeation pattern for water and the homologous alcohols and differences with respect to the stratum corneum. J Pharm Pharmacol 1983;35:28–33
- Hui X, Wester RC, Barbadillo S, et al. Ciclopirox delivery into the human nail plate. J Pharm Sci 2004;93:2545–8
- Gupta AK, Kohli Y. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br J Dermatol 2003;149:296–305